Article
Oncology
Xin-Yu Li, Lu-Yu Zhang, Xue-Yuan Li, Xi-Tao Yang, Li-Xin Su
Summary: A prognostic model based on pyroptosis-related genes was established to predict overall survival in patients with glioblastoma. The model showed good accuracy in predicting the 1-, 3-, and 5-year overall survival of GBM patients, with area under the ROC curves of 0.921, 0.840, and 0.905, respectively. Functional analysis revealed differences in immune-related processes between different risk groups.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Wenqing Gao, Yuanyuan Li, Teng Zhang, Jianglong Lu, Jiasong Pan, Qi Qi, Siqi Dong, Xiangjun Chen, Zhipeng Su, Jixi Li
Summary: This study reveals that chemokines, including CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13, are highly expressed in glioblastoma and are associated with immune cell infiltration regulation and worse patient outcomes. Among them, CCL18 is identified as a critical driver of GBM malignant behaviors.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Article
Genetics & Heredity
Huifang Xu, Linfang Zhang, Xiujuan Xia, Wei Shao
Summary: This study identified five mRNA biomarkers associated with survival in glioblastoma patients and successfully verified their prognostic value. These findings provide new prospective prognostic biomarkers for glioblastoma.
FRONTIERS IN GENETICS
(2022)
Article
Clinical Neurology
Changjun Rao, Jinghao Jin, Jianglong Lu, Chengde Wang, Zerui Wu, Zhangzhang Zhu, Ming Tu, Zhipeng Su, Qun Li
Summary: This study constructed a risk score based on preoperative peripheral blood tests and conventional MRI to predict the prognosis of GBM patients. The developed nomogram model exhibited appropriate predictive power, and vascular endothelial growth factor A (VEGFA) was identified as the key peripheral blood test-related gene associated with poor prognosis.
FRONTIERS IN NEUROLOGY
(2022)
Review
Oncology
Nathalie Olympios, Vianney Gilard, Florent Marguet, Florian Clatot, Frederic Di Fiore, Maxime Fontanilles
Summary: Glioblastoma is the most common malignant primary brain tumor in adults, with an incidence of 2 to 3 cases per 100,000 persons in North America and Europe. Alterations in the telomerase reverse transcriptase promoter, highly recurrent in all glioblastomas, including both IDH wild type and mutated, are potential mechanisms enabling cancer growth.
Article
Biochemistry & Molecular Biology
Pawel Jarmuzek, Piotr Defort, Marcin Kot, Edyta Wawrzyniak-Gramacka, Barbara Morawin, Agnieszka Zembron-Lacny
Summary: Cytokines play a critical role in tumor cell development and multiplication, but their involvement in glioblastoma (GBM) is still not well understood. This study evaluated the inflammatory profile and identified potential molecular signatures specific to GBM. The results showed elevated neutrophils and neutrophil-to-lymphocyte ratio (NLR) in GBM patients, with an inverse correlation between neutrophil count and survival time. Pro-inflammatory cytokines IL-1 beta, IL-6, and IL-8 were significantly higher in GBM, while TNF alpha and HMGB1 were lower. IL-6 and IL-8 had the highest diagnostic potential for clinical prognosis, with a three-fold higher probability of GBM development above certain threshold values.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Anne Clavreul, Jean-Michel Lemee, Gwenaelle Soulard, Audrey Rousseau, Philippe Menei
Summary: The survival outcomes of glioblastoma (GB) patients undergoing standard therapy are heterogeneous. Preoperative high neutrophil-to-lymphocyte ratio (NLR), high platelet count, and low red blood cell count were identified as independent prognostic factors for poorer overall survival (OS) in patients with IDH-wildtype GB treated with standard therapy. Additionally, high NLR and derived NLR (dNLR) were found to be poor prognostic factors for both progression-free survival (PFS) and OS in these patients, with scores based on preoperative platelet and RBC counts plus NLR or dNLR being identified as independent prognostic factors for PFS and OS.
Article
Pathology
Enrico Franceschi, Dario De Biase, Vincenzo Di Nunno, Annalisa Pession, Alicia Tosoni, Lidia Gatto, Giovanni Tallini, Michela Visani, Raffaele Lodi, Stefania Bartolini, Alba Ariela Brandes
Summary: In this study, ALK gene alterations were identified in patients with IDH wt GBM, with some rare alterations observed. However, the overexpression of ALK did not influence survival outcomes in these patients.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Oncology
Zhou Zhou, Jing Yuan, Hongtao Chen, Li Ping Zhan, Er yi Sun, Bo Chen
Summary: It was found that glioblastoma (GBM) patients with distant extension have a worse prognosis, and age, surgery, radiotherapy, and chemotherapy are independent risk factors for these patients. A scoring system was established to predict the overall survival rate of these patients, accurately predicting the survival rates at 0.25 years, 0.5 years, and 1 year.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Elise Aquilanti, Lauren Kageler, Patrick Y. Wen, Matthew Meyerson
Summary: Glioblastoma is the most common primary malignant brain tumor in adults, with TERT promoter mutations playing a key role in providing cancer cells with immortality. Telomerase as a potential therapeutic target may be the Achilles' heel of glioblastoma.
Article
Oncology
Maikel Verduin, Sergey Primakov, Inge Compter, Henry C. Woodruff, Sander M. J. van Kuijk, Bram L. T. Ramaekers, Maarten te Dorsthorst, Elles G. M. Revenich, Mark ter Laan, Sjoert A. H. Pegge, Frederick J. A. Meijer, Jan Beckervordersandforth, Ernst Jan Speel, Benno Kusters, Wendy W. J. de Leng, Monique M. Anten, Martijn P. G. Broen, Linda Ackermans, Olaf E. M. G. Schijns, Onno Teernstra, Koos Hovinga, Marc A. Vooijs, Vivianne C. G. Tjan-Heijnen, Danielle B. P. Eekers, Alida A. Postma, Philippe Lambin, Ann Hoeben
Summary: This study demonstrates the potential of combining MRI and clinical features for predicting prognosis in GBM patients, with promising but yet to be validated results in predicting tumor markers. Further optimization and prospective studies are needed.
Article
Medicine, General & Internal
Di Zhang, Jixin Luan, Bing Liu, Aocai Yang, Kuan Lv, Pianpian Hu, Xiaowei Han, Hongwei Yu, Amir Shmuel, Guolin Ma, Chuanchen Zhang
Summary: This study compared the performance of radiomics-based machine learning survival models in predicting the prognosis of GBM patients. The results showed that deep learning algorithms based on radiomics outperformed the traditional method in predicting the overall survival of GBM patients, with the DeepSurv model exhibiting the best predictive ability.
FRONTIERS IN MEDICINE
(2023)
Review
Oncology
Jinhai Tang, Zhenghao Dong, Junxiu Sheng, Ping Yang, Wanying Zhao, Juan Xue, Qizheng Li, Li Lv, Xiupeng Lv
Summary: Glioblastoma, the most dangerous type of glioma, has a high fatality rate and poor prognosis. It is necessary to develop clinical parameters to evaluate patients' conditions and predict their prognosis. Studies have shown that sarcopenia, measured by temporal muscle thickness, is associated with a poor prognosis in cancer patients. This review highlights the potential of using temporal muscle thickness as an independent predictor of survival in glioblastoma patients and evaluates recent research findings on its association with prognosis.
FRONTIERS IN ONCOLOGY
(2023)
Article
Clinical Neurology
Lingnan Zheng, Min Yu, Shuang Zhang
Summary: Accumulating evidence indicates an inverse relationship between atopic diseases and glioma susceptibility, with improved prognosis in glioma patients. This study focuses on the impact of basophils on the prognosis of patients with glioblastoma (GBM), showing that increased pre-operation circulating basophils may serve as a novel marker for predicting better progression free survival (PFS) in GBM patients.
NEUROSURGICAL REVIEW
(2021)
Article
Oncology
Abigail J. Harland, Claire M. Perks, Paul White, Kathreena M. Kurian, Hannah R. Barber
Summary: Studies have found that the expression levels of IGFBP-2 and GRP78 are associated with the prognosis of patients with IDH-wildtype glioblastoma. Patients with high IGFBP-2 and low GRP78 protein expression have a shorter survival time, which may serve as adverse prognostic markers for IDH-wildtype glioblastoma.
Article
Chemistry, Multidisciplinary
Benjamin Neuditschko, Anton A. Legin, Dina Baier, Arno Schintlmeister, Siegfried Reipert, Michael Wagner, Bernhard K. Keppler, Walter Berger, Samuel M. Meier-Menches, Christopher Gerner
Summary: The study reveals that the anticancer agent BOLD-100 interacts with ribosomal proteins, induces ER stress, and modulates GRP78 in cancer cells. Target-profiling experiments and cellular observations provide evidence for these changes.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2021)
Review
Oncology
Melanie Vogl, Anna Rosenmayr, Tomas Bohanes, Axel Scheed, Milos Brndiar, Elisabeth Stubenberger, Bahil Ghanim
Summary: Malignant pleural mesothelioma (MPM) is an aggressive disease with limited treatment options and poor prognosis, with asbestos exposure and chronic inflammation as main risk factors. The suppression of the specific immune system and activation of the innate immune system are crucial drivers of MPM aggressiveness, leading to unfavorable patient outcomes. Identifying new biomarkers can help personalize patient therapy, avoid ineffective treatments, and ultimately improve outcomes in this rare disease.
Article
Health Care Sciences & Services
Alicia Baumgartner, Natalia Stepien, Lisa Mayr, Sibylle Madlener, Christian Dorfer, Maria T. Schmook, Tatjana Traub-Weidinger, Daniela Loetsch-Gojo, Dominik Kirchhofer, Dominik Reisinger, Cora Hedrich, Saleha Arshad, Stefan Irschik, Heidrun Boztug, Gernot Engstler, Marie Bernkopf, Fikret Rifatbegovic, Christoph Hoeller, Irene Slavc, Walter Berger, Leonhard Muellauer, Christine Haberler, Amedeo A. Azizi, Andreas Peyrl, Johannes Gojo
Summary: Primary diffuse leptomeningeal melanomatosis (PDLMM) is a rare and aggressive cancer type with unclear treatment strategies. Clinical presentation is nonspecific, leading to delayed diagnosis, and despite diverse therapeutic approaches, overall survival remains short. The most commonly reported oncogenic driver is NRAS mutation, highlighting a biological relation to malignant melanoma and neurocutaneous melanosis. Detection of this somatic mutation in cerebrospinal fluid liquid biopsy may serve as a potential biomarker for diagnosis and monitoring of PDLMM.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Dina Baier, Beatrix Schoenhacker-Alte, Mate Rusz, Christine Pirker, Thomas Mohr, Theresa Mendrina, Dominik Kirchhofer, Samuel M. Meier-Menches, Katharina Hohenwallner, Martin Schaier, Evelyn Rampler, Gunda Koellensperger, Petra Heffeter, Bernhard Keppler, Walter Berger
Summary: Cellular energy metabolism is reprogrammed in cancer cells, leading to resistance against ruthenium-based chemotherapy drug BOLD-100 through enhanced glycolytic activity, increased lysosomal compartment, and defective downstream autophagy execution. Combining 2-deoxy-D-glucose with BOLD-100 reverses this resistance by inducing synergistic cell death and disrupting autophagy, suggesting glycolysis as a potential target to enhance BOLD-100 anticancer activity.
Article
Oncology
Melanie Biesinger, Nele Eicken, Alexander Varga, Michael Weber, Milos Brndiar, Georg Erd, Peter Errhalt, Klaus Hackner, Sarah Hintermair, Alexander Petter-Puchner, Axel Scheed, Elisabeth Stubenberger, Bahil Ghanim
Summary: Lung cancer, the second most common cancer and leading cause of cancer-related deaths globally, still lacks sufficient investigation on the prognostic value of lymph and blood vessel invasion. This study aimed to examine the separate roles of lymphatic and vascular invasion as risk factors in patients with non-small cell lung cancer (NSCLC) treated with video-assisted thoracoscopic lobectomy (VATS) and to improve risk stratification. The findings indicated that lymphatic invasion was significantly associated with various clinicopathologic factors and was an independent prognostic factor for both adenocarcinoma and squamous cell carcinoma, while blood vessel invasion showed a negative prognostic tendency. These findings suggest that lymph vessel invasion may be considered as an upstaging factor and a risk factor for adjuvant therapy after surgical resection in resectable lung cancer.
Article
Chemistry, Multidisciplinary
Philipp Fronik, Michael Gutmann, Petra Vician, Mirjana Stojanovic, Alexander Kastner, Petra Heffeter, Christine Pirker, Bernhard K. Keppler, Walter Berger, Christian R. Kowol
Summary: This study reports on a platinum(IV) prodrug based on oxaliplatin, which releases an inhibitor of glutathione biosynthesis to overcome therapy resistance. In vitro experiments showed lower anticancer activity but higher cellular uptake in resistant cells for the prodrug compared to oxaliplatin. Animal model results revealed higher tumor selectivity and enhanced antitumor activity for the prodrug.
COMMUNICATIONS CHEMISTRY
(2022)
Article
Oncology
Vivien Posa, Alessia Stefanelli, Julia H. Bormio Nunes, Sonja Hager, Marlene Mathuber, Nora May, Walter Berger, Bernhard K. Keppler, Christian R. Kowol, Eva A. Enyedy, Petra Heffeter
Summary: In addition to zinc, iron and copper also play a role in the mode of action and resistance development of COTI-2 and its derivatives. COTI-NMe2 is discovered to be a new drug candidate with improved anticancer activity and resistance profile. The study reveals that COTI-2 forms stable complexes with copper and glutathione, making it a substrate for the resistance efflux transporter ABCC1. Furthermore, the interaction of COTI-2 and its derivatives with iron, copper, and zinc ions is characterized, and their activities against drug-resistant cancer cells are investigated.
Article
Oncology
Bahil Ghanim, Dina Baier, Christine Pirker, Leonhard Muellauer, Katharina Sinn, Gyoergy Lang, Konrad Hoetzenecker, Walter Berger
Summary: This study established two new cell models of solitary fibrous tumor and found that the combination of trabectedin with ponatinib or dasatinib had synergistic effects against fusion-positive solitary fibrous tumor cells. This provides a new treatment approach for this rare and hard-to-treat disease.
Article
Pharmacology & Pharmacy
Yvonne Lerchbammer-Kreith, Michaela Hejl, Petra Vician, Michael A. Jakupec, Walter Berger, Mathea S. Galanski, Bernhard K. Keppler
Summary: Based on their drug delivery properties and activity against tumors, PAMAM dendrimers were combined with platinum(IV) complexes to improve anticancer treatment. The conjugates showed faster reduction behavior compared to the platinum(IV) complexes and exhibited significantly increased cytotoxic activity in human cell lines. In vivo experiments demonstrated tumor growth inhibition and prolonged animal survival.
Article
Chemistry, Multidisciplinary
Martin Schaier, Sarah Theiner, Dina Baier, Gabriel Braun, Walter Berger, Gunda Koellensperger
Summary: In this study, a workflow combining low-dispersion laser ablation with inductively coupled plasma time-of-flight mass spectrometry (LA-ICP-TOFMS) was presented, enabling spatial single-cell metallomics in tissue to decode cellular heterogeneity. The toolbox of single-cell metallomics was expanded by integrating the concepts of imaging mass cytometry (IMC) to utilize metal-labeled antibodies for cellular tissue profiling.
Article
Cell Biology
Livia Gruber, Maximilian Jobst, Endre Kiss, Martina Karasova, Bernhard Englinger, Walter Berger, Giorgia Del Favero
Summary: Bladder cells rely on the cytoskeletal network and endoplasmic reticulum (ER) to maintain mechanical stability. The rearrangement of ER can lead to changes in cellular mechanical properties.
CELL COMMUNICATION AND SIGNALING
(2023)
Article
Cell Biology
Alexander Ries, Astrid Slany, Christine Pirker, Johanna C. C. Mader, Doris Mejri, Thomas Mohr, Karin Schelch, Daniela Flehberger, Nadine Maach, Muhammad Hashim, Mir Alireza Hoda, Balazs Dome, Georg Krupitza, Walter Berger, Christopher Gerner, Klaus Holzmann, Michael Grusch
Summary: In this study, novel hTERT-transduced mesothelial cell and Meso-CAF models were generated and characterized, and their impact on PM cell growth was investigated.
Article
Chemistry, Inorganic & Nuclear
Alexander Kastner, Theresa Mendrina, Florian Bachmann, Walter Berger, Bernhard K. Keppler, Petra Heffeter, Christian R. Kowol
Summary: In this study, oxaliplatin(iv)-based complexes were developed as platinum(iv) prodrugs to release aspirin, which has shown antitumor activity against colon cancer. The newly synthesized complex demonstrated increased reduction stability compared to a cisplatin analog and exhibited desired prodrug properties in cell culture. A derivative with albumin-binding properties showed improved pharmacokinetics and tumor accumulation, leading to enhanced antitumor activity and overall survival in tumor-bearing mice.
INORGANIC CHEMISTRY FRONTIERS
(2023)
Article
Chemistry, Inorganic & Nuclear
Marlene Mathuber, Michael Gutmann, Mery La Franca, Petra Vician, Anna Laemmerer, Patrick Moser, Bernhard K. Keppler, Walter Berger, Christian R. Kowol
Summary: Receptor tyrosine kinase inhibitors have limitations in cancer therapy due to rapid resistance development and severe adverse effects. Researchers have synthesized cobalt(iii) complexes as hypoxia-activatable prodrugs of the clinically approved tyrosine kinase inhibitor ponatinib, showing promising in vivo anticancer activity in BCR-ABL and FGFR-driven cancer models.
INORGANIC CHEMISTRY FRONTIERS
(2021)